Healthcare / BiotechnologyNasdaqGS
$10.44
-0.04 (-0.38%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-54.6M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$652M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-32.8%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-69.8M · FCF $-54.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | — | — | — | — | — | — | $226000.00 |
| Net Income | $-69.8M | $-69.8M | $-49.6M | $-66.9M | $-63.3M | $-35.5M | $-8.3M |
| EBITDA | $-78.8M | $-78.8M | $-61.8M | $-77.7M | $-67.2M | — | — |
| EPS | -1.22 | -1.22 | -0.88 | -1.19 | -1.14 | -0.77 | — |
| Operating Margin | — | — | — | — | — | — | -3685.8% |
| Net Margin | — | — | — | — | — | — | -3663.7% |
| Balance Sheet | |||||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — | — |
| Current Ratio | 22.28 | 22.28 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-54.6M | $-54.6M | $-43.4M | $-58.8M | $-52.2M | $-30.9M | $-8.7M |
| Returns | |||||||
| ROE | -32.8% | -32.8% | -20.5% | -24.1% | -19.3% | -9.3% | 73.2% |
| Valuation | |||||||
| P/B | 2.82 | 2.82 | 1.56 | 0.51 | 1.60 | — | — |
| Growth & Yield | |||||||
| EPS Growth | -38.6% | -38.6% | 26.1% | -4.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+179.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.88 → -1.22
Residual
+179.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.